Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

NCT02027064 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT02027064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02027064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Lead sponsor
Peking University People's Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2013
Completion date
October 31, 2017
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia